Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP

Grade 3/4 anaemia, which is mainly induced by carboplatin, frequently occurs in patients treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP). However, dose reduction of carboplatin may raise concerns about the oncological outcome. This study investigated the pathologic compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Jung Hwan, Bae, Soong June, Kim, Seul‐Gi, Kim, Min Hwan, Kim, Gun‐Min, Sohn, Joohyuk, Jeong, Joon, Kim, Jee Hung, Ahn, Sung Gwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883435/
https://www.ncbi.nlm.nih.gov/pubmed/35837812
http://dx.doi.org/10.1002/cam4.5022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883435/
https://www.ncbi.nlm.nih.gov/pubmed/35837812
http://dx.doi.org/10.1002/cam4.5022

Ejemplares similares